ArticleClinical and vaccine immunology : CVI2013
A prime-boost strategy using the novel vaccine candidate, LemA, protects hamsters against leptospirosis.
Article in Clinical and vaccine immunology : CVI, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 47 citations in OpenAlex.
- Advances in ELISA-based detection of equine leptospirosis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Challenges and Strategies for Developing Recombinant Vaccines against Leptospirosis: Role of Expression Platforms and Adjuvants in Achieving Protective Efficacy.Pathogens (Basel, Switzerland) · 2023Review
- Identification of Leptospiral Protein Antigens Recognized by WC1Infection and immunity · 2022Article
- Revisiting the Development of Vaccines Against PathogenicFrontiers in immunology · 2021Review
- GspD, The Type II Secretion System Secretin ofVaccines · 2020Article
- DNA nanovaccines prepared using LemA antigen protect Golden Syrian hamsters against Leptospira lethal infection.Memorias do Instituto Oswaldo Cruz · 2020Article
- Immunoprotective Activity Induced by Leptospiral Outer Membrane Proteins in Hamster Model of Acute Leptospirosis.Frontiers in immunology · 2020Article
- Article
- Heterologous DNA prime-protein boost immunization with RecA and FliD offers cross-clade protection against leptospiral infection.Scientific reports · 2018Article
- Reverse Vaccinology: An Approach for Identifying Leptospiral Vaccine Candidates.International journal of molecular sciences · 2017Review
- A Universal Vaccine against Leptospirosis: Are We Going in the Right Direction?Frontiers in immunology · 2017Article
- Discovery of Novel Leptospirosis Vaccine Candidates Using Reverse and Structural Vaccinology.Frontiers in immunology · 2017Article
- DNA prime-protein boost based vaccination with a conserved region of leptospiral immunoglobulin-like A and B proteins enhances protection against leptospirosis.Memorias do Instituto Oswaldo Cruz · 2015Article
- Current immunological and molecular tools for leptospirosis: diagnostics, vaccine design, and biomarkers for predicting severity.Annals of clinical microbiology and antimicrobials · 2015Review
- Evaluation of the Leptospira interrogans Outer Membrane Protein OmpL37 as a Vaccine Candidate.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toward developing an effective vaccine capable of conferring heterologous protection, the putative lipoprotein LemA, which presents an M3 epitope similar to that of Listeria, was evaluated as a vaccine candidate in the hamster model of leptospirosis. LemA is conserved (>70% pairwise identity) among the pathogenic Leptospira spp., indicating its potential in stimulating a cross-protective immune response. Using different vaccination strategies, including prime-boost, DNA vaccine, and a subunit preparation, recombinant LemA conferred different levels of protection in hamsters. Significant protection against mortality was observed for the prime-boost and the DNA vaccine strategies, which showed 87.5% (P < 0.01) and 62.5% (P < 0.05) efficacy, respectively. Although the subunit vaccine preparation protected 50.0% of immunized hamsters, the level of protection was not significant. None of the hamsters in the control groups survived challenge with a virulent strain of Leptospira interrogans serogroup Icterohaemorrhagiae. Characterization of the immune response found that the strongest antibody response was stimulated by the subunit vaccine preparation, followed by the prime-boost strategy. The DNA vaccine failed to elicit an antibody response in immunized hamsters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.